Hoth Therapeutics has announced the formation of its subsidiary, Hoth Therapeutics Australia, in preparation for upcoming clinical studies.

The clinical trials will be focused on providing therapeutics for atopic dermatitis, also known as eczema, which is a dermatological disorder.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The newly formed subsidiary will oversee the preparation and execution of Hoth’s first clinical trial, which examines the efficacy and safety of BioLexa indicated for the treatment of mild-to-moderate atopic dermatitis.

The entity will also be eligible for a significant research and development (R&D) tax rebate.

It will supervise data management, medical monitoring, quality insurance, regulatory and central laboratory services to support the clinical trial of the therapeutic BioLexa.

Hoth Therapeutics CEO Robb Knie said: “We are excited by the opportunity to work with Australian researchers and members of the international pharmaceutical industry, in regards to the development of our proprietary atopic dermatitis treatment.”

“This endeavor is a significant milestone for us, as we move towards clinical trials.  Hoth is committed to working diligently with physicians, and regulators in order to successfully pilot our BioLexa Platform to the millions of people that are afflicted with atopic dermatitis.”

The new entity was formed in connection with full-service contract research organisation Novotech and financial solutions provider CoSec Consulting. Both the companies are based in Australia.

Nevada-based Hoth Therapeutics is a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from atopic dermatitis. It has exclusive worldwide rights to the BioLexa Platform.

The BioLexa Platform is a proprietary and patented antimicrobial therapeutic based on cutting-edge scientific research from University of Cincinnati.